TABLE 2.
Antibiofilm activities of representative aryl rhodanine compounds against a panel of biofilm-forming staphylococcal and enterococcal strainsa
| Organism | MBIC (μM [μg/ml]) of:
|
|||
|---|---|---|---|---|
| MBX-1240 | MBX-1246 | MBX-1384 | MBX-1427 | |
| S. aureus | ||||
| ATCC 35556 | 2.6 (1) | 4.4 (1.7) | 10.5 (3.8) | 2.6 (1) |
| MRSA-47263 | 8.8 (3.3) | 8.8 (3.3) | 12.5 (4.5) | 8.8 (3.4) |
| MRSA-58336 | 10.5 (3.9) | 10.5 (3.9) | 14.9 (5.3) | 10.5 (4.1) |
| MSSA | 14.9 (5.6) | 14.9 (5.6) | 12.5 (4.5) | 10.5 (4.1) |
| MRSA-27687 | 17.7 (6.6) | 25 (9.4) | 17.7 (6.3) | 50 (19.4) |
| NCTC 8325 | 25 (9.4) | 25 (9.4) | 12.5 (4.5) | 14.9 (5.8) |
| MRSA-14234 | 25 (9.4) | 17.7 (6.6) | 17.7 (6.3) | 25 (9.7) |
| MRSA-24102 | 25 (9.4) | 31.5 (11.8) | 19.8 (7.1) | 100 (38.7) |
| MRSA-33548 | 25 (9.4) | 35.4 (13.3) | 17.7 (6.3) | 31.5 (12.2) |
| MRSA-35392 | 25 (9.4) | 25 (9.4) | 25 (9) | 39.7 (15.4) |
| MRSA-23542 | 31.5 (11.8) | 19.8 (7.4) | 25 (9) | 25 (9.7) |
| MRSA-43349 | 35.4 (13.3) | 25 (9.4) | 12.5 (4.5) | 70.7 (27.4) |
| MW2 | 42 (15.8) | 31.5 (11.8) | 21 (7.5) | 25 (9.7) |
| MRSA-22733 | 50 (18.8) | 70.7 (26.5) | 17.7 (6.3) | 100 (38.7) |
| MRSA-38230 | 50 (18.8) | 25 (9.4) | 19.8 (7.1) | 35.4 (13.7) |
| MRSA-49404 | 63 (23.7) | 25 (9.4) | 31.5 (11.3) | 15.7 (6.1) |
| MRSA-44081 | 79.4 (29.8) | 25 (9.4) | 25 (9) | 39.7 (15.4) |
| MRSA-24209 | 100 (37.5) | 100 (37.5) | 25 (9) | 100 (38.7) |
| MRSA-1094 | 100 (37.5) | 100 (37.5) | 25 (9) | 100 (38.7) |
| S. epidermidis | ||||
| ATCC 35984 | 17.7 (6.6) | 25 (9.4) | 12.5 (4.5) | 17.7 (6.8) |
| GTC 18972 | 21 (7.9) | 50 (18.8) | 12.5 (4.5) | 17.7 (6.8) |
| 1457 | 42 (15.8) | 50 (18.8) | 12.5 (4.5) | 29.7 (11.5) |
| O-47 | 50 (18.8) | 100 (37.5) | 59.5 (21.3) | 59.5 (23) |
| CoNS | ||||
| WTBF-41 | 14.9 (5.6) | 17.7 (6.6) | 17.7 (6.3) | 17.7 (6.8) |
| WTBF-45 | 25 (9.4) | 50 (18.8) | 17.7 (6.3) | 25 (9.7) |
| WTBF-48 | 25 (9.4) | 50 (18.8) | 17.7 (6.3) | 12.5 (4.8) |
| WTBF-47 | 29.7 (11.2) | 42 (15.8) | 12.5 (4.5) | 29.7 (11.5) |
| WTBF-40 | 50 (18.8) | 59.5 (22.3) | 35.4 (12.7) | 50 (19.4) |
| WTBF-46 | 50 (18.8) | 59.5 (22.3) | 25 (9) | 70.7 (27.4) |
| E. faecalis | ||||
| ATCC 51299 (VRE) | 12.5 (4.7) | 25 (9.4) | 8.8 (3.2) | 14.9 (5.8) |
| F217 | 12.5 (4.7) | 29.7 (11.2) | 12.5 (4.5) | 14.9 (5.8) |
| F317 | 25 (9.4) | 100 (37.5) | 15.7 (5.6) | 100 (38.7) |
| ATCC 51575 | 29.7 (11.2) | 63 (23.7) | 21 (7.5) | 35.4 (13.7) |
| F177 | ≥100 (≥37.5) | ≥100 (≥37.5) | 19.8 (7.1) | 70.7 (27.4) |
| E. faecium | ||||
| EF208 | 31.5 (11.8) | 50 (18.8) | 15.7 (5.6) | 35.4 (13.7) |
| 1401 | 100 (37.5) | ≥100 (≥37.5) | 19.8 (7.1) | 79.4 (30.8) |
| EF1509 | ≥100 (≥37.5) | ≥100 (≥37.5) | 21 (7.5) | 59.5 (23) |
| F1181 | ≥100 (≥37.5) | ≥100 (≥37.5) | ≥100 (≥35.8) | ≥100 (≥38.7) |
| E. gallinarum 2392 | 84.1 (31.6) | 50 (18.8) | 17.7 (6.3) | ≥100 (≥38.7) |
| E. coli ATCC 25922 | ≥100 (≥37.5) | ≥100 (≥37.5) | ≥100 (≥35.8) | ≥100 (≥38.7) |
| P. aeruginosa PAO1 | ≥100 (≥37.5) | ≥100 (≥37.5) | ≥100 (≥35.8) | ≥100 (≥38.7) |
a
Antibiofilm activity is expressed as the MBIC, which is the lowest concentration of a compound in a twofold dilution series that inhibits biofilm formation by at least 80%. The values presented are the geometric mean MBICs obtained from at least three independent experiments.